[Retracted] Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
Table 4
Prognostic factors associated with overall survival.
Factor
Univariate analysis
Multivariate analysis
HR(95% CI)
P-value
HR(95% CI)
P-value
Age (8 vs. ≤58)
1.598(0.963∼2.653)
0.071
—
—
Gender (male vs. female)
1.442(0.858∼2.423)
0.165
—
—
PS (0 vs. 1–2)
1.145(0.700∼1.880)
0.582
—
—
Etiology (HBV vs. Other)
1.133(0.577∼2.233)
0.711
—
—
Cirrhosis (yes vs. no)
0.860(0.491∼1.501)
0.589
—
—
Tumor number (multiple vs. Single)
1.889(1.144∼3.129)
0.014
1.968(1.138∼3.396)
0.017
Child-Pugh class (A vs. B)
1.070(0.589∼1.943)
0.820
—
—
AFP level (>400 vs. ≤400)
1.042(0.628∼1.723)
0.871
—
—
PVTT statue (yes vs. no)
3.845(2.248∼6.552)
<0.001
4.251(2.360∼7.648)
<0.001
Treatment (T-MWA vs. T-CRA)
1.121(0.684∼1.843)
0.642
—
—
Note. T-MWA: TACE combined with microwave ablation; T-CRA: TACE combined with radiofrequency ablation.
